OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
| 1 | |
| 0.975 | |
| - | |
| 1 | |
| 0.975 | |
| 0.75-1.78 | |
| 119 M | |
| 113 M | |
| 74 021 K | |
| -0.44 | |
| -0.121 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Optinose, Inc. Second Quarter 2023 Conference Call and Webcast to be held August 10, 2023 at 8:00 a.m. Eastern Time Company plans to update full year 2023 XHANCE net revenue guidance on August 10 Y...
With the business potentially at an important milestone, we thought we'd take a closer look at OptiNose, Inc.'s (NASDAQ:OPTN) future prospects. OptiNose, Inc., a specialty pharmaceutical company, focu...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
